Skip to main content
Clinical Trials/CTRI/2019/06/019926
CTRI/2019/06/019926
Recruiting
Phase 4

COMPARATIVE EVALUATION OF EFFICACY AND SAFETY OF METFORMIN AND GLIMEPIRIDE WITH CONCOMITANT ROSUVASTATIN IN PATIENTS OF NON ALCOHOLIC FATTY LIVER DISEASE WITH COEXISTENT TYPE 2 DIABETES MELLITUS

nil0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
nil
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
nil

Eligibility Criteria

Inclusion Criteria

  • o NAFLD diagnosed by suggestive imaging findings (ultrasound) with
  • abnormal aminotransferase levels. AST 50\-150 U/L (1 to 3 times the
  • upper limit of normal).
  • o Concomitant with newly diagnosed T2DM.
  • o Subjects between age group 20 â?? 60 years of either sex

Exclusion Criteria

  • 1\. Hypersensitivity to metformin, glimepiride and rosuvastatin.
  • 2\. Patients with age group \< 20 years and \> 60 years.
  • 3\. Patients with Type 1 Diabetes and Type 2 diabetes with end stage
  • complications and diabetic ketoacidosis.
  • 4\. Pregnancy and lactation.
  • 5\. Patients with hypotensive states, thyroid disorders, adrenal insufficiency,
  • heart failure, respiratory disorders tuberculosis, hepatobiliary disease,
  • chronic renal disease.
  • 6\. Patients with hepatitis B \& C and significantly deranged enzymes (ALT \>
  • 3 times normal values)

Outcomes

Primary Outcomes

Not specified

Similar Trials